Total Funding
26
47
Total FundingVenture - Series Unknown raised
Growth Score 26 in past quarter
-5 pts
Heat Score 47 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
119151
SeylanMED is a biotech company that develops a targeted therapy for Seborrheic Keratosis.
Acquired by 
DermBiont
- Anna Mandinova: Scientific Founder
About the Company
SeylanMED is a biotech company that develops a targeted therapy for Seborrheic Keratosis.
SeylanMED is committed to the development of a topical Akt inhibitor as a first in class treatment for Seborrheic Keratosis (SK). Our lead drug candidate, SM-020, is the first molecularly-targeted approach for the treatment of SK.
SeylanMED is funded by
angel investors including board-certified dermatologists.
Women Founded